Pancreatic Cancer Trials in China — How to Find and Verify One
You have heard that China runs trials for KRAS variants, GPC3 CAR-T, or Claudin18.2 that may not be open elsewhere. That may be true. But "trial exists in China" is not the same as "trial is open to you." This page gives you a 10-step verification method — so you can confirm what is real before you buy a plane ticket.
Quick Answer — If You Have 30 Seconds
Yes, China runs trials that may not be open in your country. The most relevant for pancreatic cancer are: KRAS pan-inhibitors (G12D, G12V, G12R), GPC3-targeted CAR-T, and Claudin18.2 CAR-T. But three things are true simultaneously:
(1) A trial existing in China does not mean it is open to international patients. Many are domestic-only, especially early-phase.
(2) A trial being "open" does not mean you are eligible. Eligibility criteria are strict — prior lines, organ function, molecular profile.
(3) A trial being "eligible" does not mean you should join it. Phase I trials have low response rates and real risks. The decision belongs to you and your oncologist.
The right question is not "Are there trials in China?" — it is "How do I verify whether a specific trial is real, open, and right for me?" That is what the 10-step method on this page teaches.
The Common Misconception — and What Actually Matters
Myth: "If a trial exists in China, I can just go there and join it."
Reality: Most Chinese clinical trials — especially early-phase — do not accept international patients. Some do; many do not. And even when they do, the eligibility criteria are strict enough that most applicants are excluded. The first question is not "Can I get there?" — it is "Am I eligible?"
The second myth: "Chinese trials are the last chance."
Reality: China has strong trial infrastructure for KRAS, CAR-T, and some solid-tumor targets — but it is one option among several. The US, EU, Korea, Japan, and India also run relevant trials. "China" is not automatically the answer; it is a specific trial in a specific place that is the answer.
Key point: Trial access is not a country. It is a specific trial, at a specific hospital, with specific eligibility criteria, currently enrolling. Everything else is marketing.
Who This Page Is For — and Who It Is Not For
This page has one specific job. If you are here for something else, one of the other pages in the cluster will serve you better.
This page is for you if…
- You have heard that a specific trial exists in China — and you want to verify whether it is real, open, and relevant to your case
- You are considering traveling to China for a trial — and want a step-by-step verification method before you commit
- You have a KRAS G12D, G12V, G12R variant (or KRAS wild-type with a specific driver) — and want to know whether a Chinese trial might apply
- You are looking for a structured way to tell a real trial from a marketing pitch
This page is not for you if…
- You do not know your KRAS variant yet — see KRAS Biology & Targeted Therapy first
- You are considering organoid testing — see Patient-Derived Organoid Testing
- You want an independent oncology opinion — see Oncology Second Opinions
- You are looking for a general "is China good for cancer?" answer — this page does not give one, because no single country is "best"
What Patients Actually Ask About Trials in China
"I found a trial on a Chinese hospital website. The page said 'now enrolling.' I almost booked a flight. Then I asked: 'Is this open to non-Chinese patients?' The answer was no. I had spent two weeks imagining a trip that was never possible. After that, I learned to ask three questions before anything else: Is it real? Is it open to me? Am I eligible?"— 57-year-old patient, metastatic PDAC, Tehran (identity withheld)
- Is the trial I saw online actually real — and currently recruiting?
- Does the trial accept international patients at all?
- What are the eligibility criteria — and do I meet them?
- Is there a Chinese-language-only process, or is there English support?
- What costs are covered by the trial — and what do I pay myself?
- If I go, how long do I need to stay in China?
- If the trial fails, what is the plan B — and can I go home safely?
When a China Trial Actually Matters — 5 Scenarios
China trials are not "always useful" or "always useless." It depends on your variant, your line of therapy, and your eligibility. Here are five scenarios.
Scenario 1 — You carry a KRAS G12D, G12V, or G12R variant, and a pan-KRAS(ON) trial is open
China trials are highly relevant. China runs a large number of pan-KRAS inhibitor trials — including RMC-6236-class agents. If a specific trial is open to international patients and you meet eligibility, this can be a meaningful option. But verify eligibility first — many are domestic-only.
Scenario 2 — You are being considered for GPC3 CAR-T or Claudin18.2 CAR-T
China trials are highly relevant. China has the largest ecosystem of GPC3-targeted and Claudin18.2-targeted CAR-T trials globally. But early-phase CAR-T trials carry significant toxicity risk, and most are domestic-only. Ask specifically about international patient acceptance.
Scenario 3 — You have KRAS G12C, and approved drugs exist in your country
China trials are less urgent. If sotorasib or adagrasib is accessible where you live, the approved drug is usually the better path — unless the Chinese trial specifically studies a combination that may overcome resistance. Discuss with your oncologist before traveling.
Scenario 4 — Your tumor is KRAS wild-type with a driver like BRAF V600E or NTRK fusion
China trials may not be the first stop. Approved therapies exist for these drivers in many countries. The American, European, or Japanese trial ecosystems may be more relevant. China is not automatically the best destination for these variants.
Scenario 5 — You are in first-line treatment and have not yet received standard chemotherapy
China trials are usually not the first step. In first-line PDAC, FOLFIRINOX or gem/nab-paclitaxel are standard-of-care. Trials are typically considered after standard options are exhausted — not before. Discuss sequencing with your oncologist.
The 10-Step Verification Method — Before You Book Anything
Follow these ten steps in order. If a trial fails any step, it is not ready to be a serious option for you yet.
10-Step Trial Verification Checklist
Steps 1–4 are about the trial itself. Steps 5–7 are about you and the trial. Steps 8–10 are about logistics and risk.
Find the trial on ClinicalTrials.gov or ChiCTR — not just a hospital website
Search ClinicalTrials.gov (international) and ChiCTR (Chinese registry). A real trial has a registration number (NCT or ChiCTR number). If a trial is only described on a hospital marketing page and has no registry ID, treat that as a red flag.
Confirm the trial is currently recruiting — not completed or suspended
The registry entry shows a recruitment status. Look for "Recruiting" or "Not yet recruiting." "Completed" and "Active, not recruiting" mean they are not taking new patients — even if the hospital page still mentions it.
Read the eligibility criteria yourself — do not rely on a summary
Registry entries list inclusion and exclusion criteria. Read them yourself. Key items usually include: prior lines of therapy, KRAS variant, performance status (ECOG), organ function (liver, kidney, blood counts), and prior treatments. If you clearly fail one of these, the trial is not for you.
Check whether the trial accepts international patients
This is the most-missed step. Many Chinese trials are domestic-only — even when listed on international registries. Call the trial coordinator or the hospital's international office and ask directly: "Does this trial accept non-Chinese patients?" Get the answer in writing (email).
Ask who the principal investigator is — and whether they have published
Look up the PI on PubMed. A PI who has published on the drug class or the disease is a positive signal. A PI with no publications is not automatically disqualifying — but ask why. Phase I trials led by experienced PIs tend to have better safety monitoring.
Ask what the trial actually tests — phase, drug class, combination
"Phase I" means safety and dosing — not proven efficacy. "Phase II" tests efficacy. Ask: "Is this a phase I, I/II, or II? What is the primary endpoint? Is the drug alone or in combination?" A phase I trial has a real chance of no benefit — that is part of the honest picture.
Ask about the time commitment — and total stay in China
Trials typically require regular visits for screening, dosing, and monitoring. Ask: "How many visits total? How long is the screening period? Can some visits be done remotely?" For a patient traveling from abroad, this often means weeks to months in China — not days.
Clarify costs — trial-covered vs patient-paid
Sponsors usually cover the study drug and trial-related tests. But travel, accommodation, interpreter costs, standard-of-care treatments, and complications are often patient-paid. Ask for a written breakdown: "What is covered, and what will I pay out of pocket?"
Understand the visa, insurance, and legal pathway
Most international patients travel to China on a medical visa — which requires an invitation letter from the hospital. Health insurance rarely covers trial participation abroad. Ask the hospital's international office to walk you through: medical visa process, insurance options, and what happens if the trial ends or fails while you are in China.
Ask the honest question — "What if this does not work?"
Ask the trial team: "If I progress on this trial, what are my options? Can I transition to another trial? Can I return to my home country for care?" A trial that has a Plan B is a trial run by a team that thinks ahead. A trial that promises "it will work" is not being honest with you.
5 Red Flags — When a "Trial" Is Not a Trial
In the medical-tourism space, some "trials" are not actually trials. Here are five warning signs.
Warning Signs in Trial Marketing
If you see any of these, pause — and verify further before proceeding.
No registration number
Every legitimate trial has an NCT or ChiCTR number. If a "trial" cannot give you a registration number, it is not a registered trial. Ask for it in writing.
No published protocol or eligibility criteria
Real trials publish their inclusion/exclusion criteria. If you are told "just send your records and we will see," without any published eligibility criteria, that is not standard trial process — it is closer to a sales pitch.
Upfront payment to a broker for "trial enrollment"
Legitimate trials do not charge patients for enrollment. If a broker asks for a payment to "secure your spot" or "guarantee eligibility," that is not standard practice — it is a red flag. Legitimate coordination fees (translation, visa support) are different — but enrollment itself should not be paid.
Promises of "high response rates" without published data
If a trial is described with impressive response rates but no published data or trial identifier is given, that is a marketing claim, not a clinical fact. Ask: "Where is this response rate published? Can you give me the citation?"
Pressure to decide immediately — "last spot"
Trials do not use urgency tactics. If a broker or hospital says "the last spot is closing tomorrow — you must decide now," that is a sales technique, not a clinical process. Real trials will give you time to review eligibility and consult your oncologist.
Frequently Asked Questions
Do Chinese trials accept international patients?
Some do — but many do not. Early-phase trials (phase I, phase I/II) are more often domestic-only. Later-phase trials at large academic centers are more likely to accept international patients. This is the single most important question to ask first — before considering cost, visa, or travel. Get the answer in writing from the hospital's international office.
Where can I search for pancreatic cancer trials in China?
Two registries are the starting point: ClinicalTrials.gov (search "pancreatic" and filter by country: China) and ChiCTR (the Chinese registry). You can also review publications on PubMed — recent Chinese PDAC trial papers often mention ongoing trials in the discussion. Never rely on a hospital marketing page alone.
What does a "pan-KRAS(ON) inhibitor" trial mean — and how do I know if I qualify?
"Pan-KRAS(ON)" refers to drugs designed to inhibit multiple KRAS variants (G12D, G12V, G12R, etc.) — not just G12C. These are typically phase I or phase I/II trials. Eligibility usually requires: a confirmed KRAS variant (with a specific list of accepted variants), prior lines of therapy (often 1–2+), performance status 0–1, and adequate organ function. Read the inclusion/exclusion criteria yourself (step 3 of the checklist). If any criterion clearly excludes you, do not pursue that trial further.
Are trials in China free?
Partially. Trial sponsors usually cover the study drug and trial-related tests (imaging, blood work, protocol biopsies). But travel, accommodation, interpreter costs, standard-of-care treatments outside the trial, and complications are often patient-paid. Ask for a written breakdown of what is covered and what is not (step 8). Do not assume "trial" means "free."
How long do I need to stay in China if I join a trial?
It varies widely. Typically: 1–2 weeks for screening, then regular visits every 1–3 weeks for dosing and monitoring. In total, most patients spend several weeks to several months in China — not days. Some later visits may be possible by telemedicine or at a local partner site, but the trial sponsor decides this. Ask step 7 of the checklist to get a specific answer.
What happens if the trial does not work?
This is the most important question to ask (step 10). A well-run trial will have a plan: either transitioning you to a different trial, returning you to standard care, or supporting your return home. A trial that promises "it will work" is not honest. A trial that has a Plan B is a trial worth considering. Ask in writing.
Is China "better" than other countries for pancreatic cancer trials?
No country is "better." China has specific strengths: a large KRAS inhibitor trial ecosystem, the largest GPC3 CAR-T and Claudin18.2 CAR-T trial pipelines globally, and high-volume academic centers. The US, EU, Korea, and Japan also have strong trial ecosystems — especially for early-phase and combination trials. The right choice depends on your variant, prior therapy, and eligibility. For KRAS interpretation, see the KRAS page; for testing, see the Organoid page; for expert review, see the Second Opinion page.
If a Trial in China Left You With More Questions Than Answers
We are not here to convince you to travel to China — or to stay home. If you have questions this page did not answer — about a specific trial, about eligibility, or about how to compare a Chinese trial to options in your country — you can share them with us.
We reply within 48 hours. If a China trial is not right for your case, we will say so honestly — and help you look elsewhere.
Continue Your Pancreatic Cancer Research
This page is one of four focused resources. If your next question is about molecular interpretation, functional testing, or expert review, these are the natural next pages.
KRAS Mutations & Targeted Therapy
What each KRAS variant means — approved drugs vs trials, and a 10-question NGS report checklist.
Read the KRAS guidePatient-Derived Organoid Testing
What organoid testing can and cannot tell you — and 12 questions to ask the lab before you commit.
Learn about organoidsOncology Second Opinions
How to seek an independent oncology opinion — and what records and molecular results a meaningful review requires.
Explore second opinionsReferences
- U.S. National Library of Medicine — ClinicalTrials.gov. Public registry of clinical studies. clinicaltrials.gov
- Chinese Clinical Trial Registry (ChiCTR). chictr.org.cn
- World Health Organization — International Clinical Trials Registry Platform (ICTRP). who.int/clinical-trials-registry-platform
- National Medical Products Administration (NMPA), China — Regulatory information. nmpa.gov.cn
- PubMed — Biomedical literature database. pubmed.ncbi.nlm.nih.gov
- National Comprehensive Cancer Network (NCCN) — Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. nccn.org
- CancerCareE — Financial Transparency and Editorial Policy. cancercaree.com/financial-transparency/